CPI-0610 is a drug which acts as a
BET inhibitor, mainly acting at the
BRD2 and
BRD4 subtypes. It has potential applications in the treatment of various forms of
cancer.[1][2][3][4]
^Raythatha J, Arnold L (November 2019). "The future of epigenetic therapy: CPI-0610 for the treatment of myeloidfibrosis". Epigenomics. 11 (14): 1553–1555.
doi:
10.2217/epi-2019-0274.
PMID31729905.
CPI-0610 is a drug which acts as a
BET inhibitor, mainly acting at the
BRD2 and
BRD4 subtypes. It has potential applications in the treatment of various forms of
cancer.[1][2][3][4]
^Raythatha J, Arnold L (November 2019). "The future of epigenetic therapy: CPI-0610 for the treatment of myeloidfibrosis". Epigenomics. 11 (14): 1553–1555.
doi:
10.2217/epi-2019-0274.
PMID31729905.